Phase III trial shows crizotinib superior to single-agent chemotherapy for ALK-positive lung cancer
Head-to-head study compares of crizotinib with standard chemotherapy in this patient group
Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
Head-to-head study compares of crizotinib with standard chemotherapy in this patient group
New trial results on pazopanib and temsirolimus have important implications for patients
Debate at ESMO 2012 Congress focuses on whether there is enough evidence to start using aspirin to reduce the risk of colorectal cancer
Study opens a new door to more personalised treatment of advanced breast cancer
New findings highlight the challenges of managing blood clotting in cancer patients
Long awaited results constitute a further milestone
Phase III data reported at ESMO 2012
ESMO welcomes the recent EC proposal which will facilitate patient access to innovative treatments on an EU-wide level
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.